Skip to main content

Table 1 Characteristics of the study population

From: Serum and bone pentosidine in patients with low impact hip fractures and in patients with advanced osteoarthritis

  Male Female
Fracture Controls Osteoarthritis Fracture Controls Osteoarthritis
Number of subjects 21 25 49 15
Age (years) 77.3 ± 9,1a 64.3 ± 10.9 77.3 ± 11.0 68.0 ± 7.9
Height (cm) 174.0 ± 7.0 176.0 ± 5.1 161.9 ± 6.9 162.9 ± 7.5
Weight (kg) 75.9 ± 15.0 b 89.7 ± 11.5 68.7 ± 15.9 79.0 ± 18.0
Prevalent fracture (No.) 2 0 21 a 0
Glucocorticoids (No.) 1 0 6 1
Smoking (No.) 2 2 5 1
Diabetes (No.) 3 6 11 3
Creatinine (μmol/l) 107 ± 33.9 97.6 ± 21.7 90.9 ± 29.1 79.6 ± 9.1
Bone pentosidine (nmol/g dry bone mass) c 2.96 a 1.10 2.57 a 0.93
0.55;6.80 0.41;2.41 0.75;5.11 0.45;1.98
Serum pentosidine (nmol/l) c 73.6 a 27.1 71.5 a 30.3
48.4; 417.4 15.46;80.3 31.4;154.6 16.2;108.0
  1. a:p < 0.001; b:p < 0.005; c:Median a 95 % CI